Southeast Asia Breast Cancer Therapeutics Market 2022 Southeast Asia Breast Cancer Therapeutics Market | Page 2

Triple-negative breast cancer (TNBC) is a setting with incredibly high unmet needs, with no
targeted therapy options being available. Chemotherapy is the mainstay of treatment in this
setting. For HR-positive disease, endocrine therapies are the primary treatment.
Survival for HER2-positive breast cancer patients has increased, due to established disease
management strategies using numerous combinations of chemotherapy along with targeted
therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). These newer therapies
are expected to significantly improve survival outcomes in all lines of the disease. The introduction
of Herceptin, the first HER2-targeting agent for metastatic disease, greatly improved the outcome
of patients with HER2-positive breast cancer, bringing survival rates close to those of HER2-
negative, HR-positive breast cancer.
In most Southeast Asian countries, the highest unmet need lies in the lack of a defined treatment
plan for the disease, poor affordability, and patients continuing to rely on the use of
chemotherapies in the later lines of treatment. It is important for drug companies to consider the
evolving reimbursement landscape when determining pricing strategies across the Southeast Asian
markets, because this will significantly impact the uptake of premium drugs.
Read Sample report of this Category:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Scope
The current Southeast Asia breast cancer market contains well-established novel targeted products
such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as
Ibrance.
- Which drugs are used as the standard treatment in each setting of the disease?
- What are the competitive advantages of the existing novel drugs?
- Do branded therapies show continued growth, and how does their expected uptake influence the
market growth over the forecast period?
There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types
and molecular targets, including those that are well established in breast cancer, and novel, first-
in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline
to improve treatment for TNBC?
- Targets that are not currently represented by marketed products are virtually absent from the
late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target
novel pathways?
Follow Us: